1 – 4 of 4
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer—A Narrative Review
(
- Contribution to journal › Scientific review
-
Mark
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
(
- Contribution to journal › Article
- 2018
-
Mark
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab : Results from the Phase II PROMIX trial
(
- Contribution to journal › Article
- 2011
-
Mark
Value of post-operative reassessment of estrogen receptor alpha expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer
(
- Contribution to journal › Article